phorbolol myristate acetate has been researched along with imidazolidines in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barrett, J; Blotner, S; Busse-Reid, R; DeSchepper, S; Deutsch, J; Goelzer, P; Lee, L; Niu, H; Peck, R; Rueger, R; Weissgerber, G | 1 |
1 trial(s) available for phorbolol myristate acetate and imidazolidines
| Article | Year |
|---|---|
The safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of RO5068760, an MEK inhibitor, in healthy volunteers: assessment of target suppression.
Topics: Adolescent; Adult; Aged; Biomarkers; Dose-Response Relationship, Drug; Double-Blind Method; Drug Evaluation, Preclinical; Extracellular Signal-Regulated MAP Kinases; Half-Life; Humans; Imidazolidines; Intestinal Absorption; Leukocytes, Mononuclear; Male; MAP Kinase Signaling System; Metabolic Clearance Rate; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Models, Biological; Phenylbutyrates; Phosphorylation; Protein Kinase Inhibitors; Tetradecanoylphorbol Acetate; Young Adult | 2010 |